Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study.
about
Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literatureImmune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression.Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study.Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptomsThe temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review.Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways.Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis.Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.Therapeutic strategies for treatment of inflammation-related depression.Sleep quality in patients with Behçet's disease.Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms.Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial.
P2860
Q34769962-5F313F4B-AF0D-4285-95E8-FCFFD0CDB87EQ36146367-6B8AC31D-D5CE-4582-86E2-F0E85350EF15Q37184586-C33C2E20-6329-4960-9F92-5C39EC1B5B8AQ37641257-016BA7DB-E160-4137-B4E8-8ACDB55B6B7CQ38067080-8D6A8423-0A31-460A-83A4-50B9D84AD866Q38122650-C7195D7E-44A6-435A-B686-B5ACC7277310Q40156599-92AB1A13-265D-48E8-84CA-25E80FAB79D9Q43538492-E0A16691-8CD7-4CBB-8B64-36A728A6967DQ44843342-7B372509-7C7C-4923-B4CA-0173BCF9C7C8Q47785792-270C7AB0-836E-4049-B657-DEE80F47B674Q48032029-4CF10810-2B62-47A6-970A-805C886BFE5CQ48226009-9C9609F7-8A54-46A2-A7E6-54DD6CA9A4F6Q55223606-0FA0E1D5-2256-45D9-8E7E-AA953CAA9AC3
P2860
Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@en
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@nl
type
label
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@en
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@nl
prefLabel
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@en
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@nl
P2093
P356
P1476
Tumour necrosis factor blockad ...... nical, proof-of-concept study.
@en
P2093
Carolyn Paterson
David Wyper
James Patterson
John McLean
Jonathan Cavanagh
Moira McDonald
P304
P356
10.1136/ARD.2009.107912
P407
P577
2010-04-06T00:00:00Z